NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free PAVM Stock Alerts $1.85 -0.02 (-1.07%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$1.84▼$1.8750-Day Range$1.83▼$3.0852-Week Range$1.60▼$9.00Volume18,493 shsAverage Volume65,342 shsMarket Capitalization$16.96 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get PAVmed alerts: Email Address PAVmed MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,035.1% Upside$21.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.34Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.70 out of 5 starsMedical Sector565th out of 909 stocksSurgical & Medical Instruments Industry63rd out of 96 stocks 3.0 Analyst's Opinion Consensus RatingPAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePAVmed has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PAVM. Previous Next 0.0 Dividend Strength Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.Environmental SustainabilityThe Environmental Impact score for PAVmed is -0.78. Previous Next 3.0 News and Social Media Coverage News SentimentPAVmed has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PAVmed this week, compared to 1 article on an average week.Search Interest9 people have searched for PAVM on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows3 people have added PAVmed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.93% of the stock of PAVmed is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About PAVmed Stock (NASDAQ:PAVM)PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More PAVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PAVM Stock News HeadlinesApril 18, 2024 | americanbankingnews.comPAVmed (NASDAQ:PAVM) Share Price Crosses Below 50-Day Moving Average of $2.19April 17, 2024 | msn.comPAVmed (PAVM) Price Target Decreased by 8.51% to 10.97April 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product CommercializationMarch 29, 2024 | seekingalpha.comPAVmed Inc. (PAVM) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for PAVmed with Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price TargetMarch 28, 2024 | finance.yahoo.comQ4 2023 PAVmed Inc Earnings CallMarch 27, 2024 | finance.yahoo.comPAVmed Full Year 2023 Earnings: EPS Beats ExpectationsApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 26, 2024 | prnewswire.comPAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial ResultsMarch 25, 2024 | markets.businessinsider.comWhat Wall Street expects from PAVmed's earningsMarch 25, 2024 | tmcnet.comNovosound secures patent for wireless wearable ultrasound imaging platformMarch 21, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationMarch 21, 2024 | prnewswire.comPAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpXMarch 13, 2024 | prnewswire.comPAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024March 12, 2024 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024March 2, 2024 | morningstar.comPAVmed Inc PAVMFebruary 29, 2024 | finance.yahoo.comPAVmed Inc.'s (NASDAQ:PAVM) Intrinsic Value Is Potentially 66% Above Its Share PriceFebruary 22, 2024 | benzinga.comPAVmed Stock (NASDAQ:PAVM) Dividends: History, Yield and DatesFebruary 16, 2024 | finance.yahoo.comLucid Diagnostics Provides Update Regarding World Trade Center Health ProgramFebruary 16, 2024 | prnewswire.comLucid Diagnostics Provides Update Regarding World Trade Center Health ProgramFebruary 15, 2024 | prnewswire.comLucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional TestimonyFebruary 10, 2024 | msn.comPAVmed Inc. Grants Shareholders Lucid Diagnostics DividendFebruary 8, 2024 | finance.yahoo.comLucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and SurvivorsJanuary 18, 2024 | finance.yahoo.comWhat Does PAVmed Inc.'s (NASDAQ:PAVM) Share Price Indicate?December 16, 2023 | msn.comPAVmed (PAVM) Price Target Increased by 685.71% to 21.04December 11, 2023 | finance.yahoo.comPAVmed Provides Additional Details for Upcoming Stock Dividend to ShareholdersSee More Headlines Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/24/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PAVM CUSIPN/A CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,023.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.3264) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,180,000.00 Net Margins-2,617.25% Pretax Margin-3,232.59% Return on EquityN/A Return on Assets-85.99% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.45 Sales & Book Value Annual Sales$2.45 million Price / Sales7.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.35) per share Price / Book-0.56Miscellaneous Outstanding Shares9,170,000Free Float8,016,000Market Cap$17.15 million OptionableOptionable Beta0.85 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Lishan Aklog M.D. (Age 58)Chairman & CEO Comp: $945.09kMr. Dennis M. McGrath CPA (Age 67)President, CFO & Corporate Secretary Comp: $663.38kMr. Shaun M. O'Neill M.B.A. (Age 41)Executive VP & COO Comp: $447.47kDr. Brian J. deGuzman M.D. (Age 59)Executive VP, Chief Technology & Compliance Officer Comp: $427.6kDr. Suman M. Verma M.D.Ph.D., Senior VP of Molecular Genetics & Chief Scientific OfficerMichael ParksVice President of Investor RelationsMr. Michael Adam Gordon (Age 50)Executive VP, General Counsel & Secretary Dr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality OfficerDr. Victoria T. Lee M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsMeihua International Medical TechnologiesNASDAQ:MHUASTRATA Skin SciencesNASDAQ:SSKNAkiliNASDAQ:AKLIT2 BiosystemsNASDAQ:TTOOPetVivoNASDAQ:PETVView All CompetitorsInstitutional OwnershipXML Financial LLCSold 144,657 shares on 2/14/2024Ownership: 0.128%View All Institutional Transactions PAVM Stock Analysis - Frequently Asked Questions Should I buy or sell PAVmed stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PAVM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAVM, but not buy additional shares or sell existing shares. View PAVM analyst ratings or view top-rated stocks. What is PAVmed's stock price target for 2024? 1 equities research analysts have issued 12 month price targets for PAVmed's shares. Their PAVM share price targets range from $21.00 to $21.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,035.1% from the stock's current price. View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts. How have PAVM shares performed in 2024? PAVmed's stock was trading at $4.12 at the start of the year. Since then, PAVM shares have decreased by 55.1% and is now trading at $1.85. View the best growth stocks for 2024 here. When is PAVmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PAVM earnings forecast. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) announced its earnings results on Tuesday, March, 26th. The company reported ($1.57) earnings per share for the quarter. The business earned $1.05 million during the quarter. When did PAVmed's stock split? PAVmed shares reverse split on the morning of Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP). How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PAVM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceThe Greatest Bull Market in Crypto History…Weiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.